Thus, CD64+ LILRA2+ CD32a+ CD4+ T-cell populations that increase in proportion during primary HIV infection and cART treatment may be more prone to activation through the engagement of CD32a, CD64, or LILRA2 activating receptors. The gene discussed is LILRA2; the disease is HIV infectious disease.